Active, not recruitingPhase 3NCT04225871
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
Studying Adult-onset myasthenia gravis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UCB Biopharma SRL
- Principal Investigator
- UCB Cares001 844 599 2273
- Intervention
- zilucoplan (RA101495)(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (30)
- Mg0011 41, Mobile, Alabama, United States
- Mg0011 116, Phoenix, Arizona, United States
- Mg0011 31, Irvine, California, United States
- MG0011 4, Los Angeles, California, United States
- Mg0011 220, Pasadena, California, United States
- Mg0011 160, San Francisco, California, United States
- Mg0011 24, New Haven, Connecticut, United States
- Mg0011 27, Washington D.C., District of Columbia, United States
- Mg0011 25, Tampa, Florida, United States
- Mg0011 135, Augusta, Georgia, United States
- Mg0011 188, Glenview, Illinois, United States
- Mg0011 156, Indianapolis, Indiana, United States
- Mg0011 32, Kansas City, Kansas, United States
- Mg0011 33, Detroit, Michigan, United States
- Mg0011 49, East Lansing, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04225871 on ClinicalTrials.govOther trials for Adult-onset myasthenia gravis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen
- RECRUITINGPHASE2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGNANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPHASE1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company
- RECRUITINGPHASE4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.